# Before we begin: Morgan Lewis and Global Technology

Be sure to follow us at our website and on social media:

Web: www.morganlewis.com/sectors/technology


Twitter: @MLGlobalTech

LinkedIn Group: ML Global Tech

Check back to our Technology May-rathon page frequently for updates and events covering the following timely topics:

21st Century Workplace		Medtech, Digital Health and Science
Artificial Intelligence and Automation	Fintech	Mobile Tech
Cybersecurity, Privacy and Big Data	Global Commerce	Regulating Tech





## **Overview**


- I. Market Trends in Digital Health Company Financings
- II. What is a Seed Financing?
- III. Considerations in Structuring a Seed Financing
- IV. Seed Financing Deal Structures
- V. Common Stock Deals
- VI. Series Seed Preferred Stock Deals
- VII. Convertible Debt Deals
- VIII. SAFE Deals
- IX. Questions




#### **HEALTHCARE INVESTMENT TRENDS**

# Healthcare funding hit a new high in Q1'21

Quarterly global healthcare funding and deal count, Q2'18 - Q1'21




## 25 \$100M+ mega deals accounted for two-thirds of total Q1 2021 funding



Source: Rock Health Digital Health Venture Funding Database and Analysis, data through March 31, 2021

## Series A, B, and C deal sizes continue to trend up through Q1 2021




Note: Series D-F deals are excluded in this analysis, given that they represent a huge swath of heterogeneous, late-stage deals that lump together a wide range of deals. The purpose of this analysis is to show the trends in early-to mid-stage deals. Source: Rock Health Digital Health Venture Funding Database and Analysis, data through March 31, 2021

PRESENTATION @ 2021 ROCK HEALTH

# Q1'21 saw a slight uptick in early-stage deals

Percentage share of global healthcare deals by stage, Q2'18 - Q1'21




**CBINSIGHTS** 

Note: "Early-stage" includes convertible note, angel, seed, and Series A rounds. "Mid-stage" includes Series B and Series C rounds. "Late-stage" includes Series D, Series E+, growth equity, and private equity rounds. "Other" includes unattributed and corporate minority rounds.

19




# **Seed Financing**





# **Considerations in Structured Seed Financings**



Who are the Investors and What are their Preferences?



**How Much Capital** is Being Invested?



What are the Costs?




What is the Timing?



Any Specific Considerations?





## **Common Stock**

## What is It?

· Most basic form of equity

#### What are the Terms?

- Generally, to elect directors, receive any dividends, share in any proceeds upon liquidation
- Generally, no special "investor-style" rights

## What are the Advantages?

- Low transaction costs
- From the company's perspective, investors have very limited economic and control rights

## What are the Disadvantages?

 From the investor's perspective, investors have very limited economic and control rights

## When is it Used?

- Founder financings
- Maybe friends and family financings

## **Series Seed Preferred Stock**

## What is It?

· A "special" form of equity

#### What are the Terms?

• Liquidation Preference, Dividends, Pre-emptive Rights, Board Representation, Protective Provisions, Information Rights, Access Rights, and More

## What are the Advantages?

- From the investor's perspective, a negotiated set of specific economic and control rights
- From the company's perspective, the ability to attract smart money

## What are the Disadvantages?

- Higher transaction costs
- · Longer time to closing

#### When is it Used?

- Venture capital financings
- Sophisticated angel financings

## **Convertible Debt**

## What is It?

· A debt security that may convert into an equity security

## What are the Terms?

- Principal Amount, Interest Rate, Maturity Date, Discount, Valuation Cap
- Conversion Features (Qualified Financing, Non-Qualified Financing, Change of Control, Maturity

## What are the Advantages?

- Punts the valuation conversation, if no Valuation Cap
- Low transaction costs
- Shorter time to closing

## What are the Disadvantages?

- From the investor's perspective, their stockholder rights are not vet set
- From the company's perspective, the debt could mature and become due and payable

#### When is it Used?

• Very Often (especially in smaller raises and earlier raises)

## **SAFEs**

## What is It?

"Simple" Agreement for Future Equity

## What are the Terms?

Similar to a note with no interest of maturity

## What are the Advantages?

- · Theoretically low transaction costs
- · Theoretically shorter time to closing

## What are the Disadvantages?

• From the investor's perspective, an irrevocable commitment of capital with a hope of fair treatment in the future

## When is it Used?

 Incubator financings, very early financings, very small financings, West Coast deals



# **Biography**



Benjamin David Novak
Partner
502 Carnegie Center
Princeton, NJ 08540
+1.609.919.6612
benjamin.novak@morganlewis.com

Benjamin David Novak is an active angel investor in early stage technology companies located on the East Coast of the United States. In addition to being an angel investor, Ben is a Partner with Morgan Lewis where he represents technology companies, angel investors, venture capital funds, and private equity firms. He is an active member of the venture community, serving on numerous advisory boards and regularly speaking at tech events, judging venture conferences, and lecturing on technology, entrepreneurship, and investing at colleges and universities.

# **Biography**



Jessica Lee
Associate
502 Carnegie Center
Princeton, NJ 08540
+1.609.919.6675
jessica.lee@morganlewis.com

Jessica Lee counsels clients on diverse corporate transactions, including license, commercialization and collaboration agreements, mergers and acquisitions, joint ventures, and strategic partnerships. Other areas of work involve finance, restructuring, securities, and corporate governance. Her clients include emerging growth, technology, financial services, and life science companies.

## **Our Global Reach**

Africa Latin America Asia Pacific Middle East North America Europe

#### **Our Locations**

Abu Dhabi Moscow New York Almaty Nur-Sultan Beijing\* Boston **Orange County** 

Brussels **Paris** 

Century City Philadelphia Chicago Pittsburgh Dallas Princeton Dubai San Francisco Frankfurt Shanghai\* Hartford Silicon Valley Hong Kong\* Singapore\*

Houston Tokyo

London Washington, DC Los Angeles

Wilmington

Miami



## Morgan Lewis

Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan, Lewis & Bockius is a separate Hong Kong general partnership registered with The Law Society of Hong Kong. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

# THANK YOU

- © 2021 Morgan, Lewis & Bockius LLP
- © 2021 Morgan Lewis Stamford LLC
- © 2021 Morgan, Lewis & Bockius UK LLP

Morgan, Lewis & Bockius UK LLP is a limited liability partnership registered in England and Wales under number OC378797 and is a law firm authorised and regulated by the Solicitors Regulation Authority. The SRA authorisation number is 615176.

Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan, Lewis & Bockius is a separate Hong Kong general partnership registered with The Law Society of Hong Kong. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

This material is provided for your convenience and does not constitute legal advice or create an attorney-client relationship. Prior results do not guarantee similar outcomes. Attorney Advertising.